Drug intelligence / Profile preview

F# 13418-148

Development stage: Unknown
Lead developer: Johnson & Johnson Consumer Inc. (J&JCI)
Modality: Small Molecules
Administration: Ophthalmic

Overview

F# 13418-148 is an investigational over-the-counter (OTC) ophthalmic solution developed by Johnson & Johnson Consumer Inc. for the treatment of ocular redness (red eye). It is a combination formulation containing tetryzoline (tetrahydrozoline) 0.05% and glycerin 0.40%. Tetryzoline is an alpha-adrenergic agonist that acts as a vasoconstrictor to reduce conjunctival congestion and redness, while glycerin serves as a lubricant and ocular protectant to soothe minor irritation. The formulation was evaluated in a Phase III clinical trial (NCT03198000) to demonstrate therapeutic equivalence and efficacy in healthy adults with red eyes. It is administered topically as eye drops.

Other names: tetrahydrozoline + glycerintetryzoline + glycerin

Targets

ADRA1A (α1A)

Beyond the preview

Go deeper on F# 13418-148.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F# 13418-148.

Explore the full profile